Endocrinology · Growth Hormone DeficiencyRegulatory Approvalregulatorymid-term

FDA Accepts Supplemental NDA for MACRILEN by Aeterna Zentaris

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 12:31:35 PM

Assessment confidence: 53% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of the supplemental NDA for MACRILEN signifies a potential expansion of its indications, which could strengthen Aeterna Zentaris' competitive position in the endocrinology sector. This development warrants close monitoring as it may open new market opportunities and impact competitive dynamics in growth hormone therapies. Regulatory context from FDA (FDA AP — MACRILEN (SUPPL)) supports the near-term read. Assessment grounded in 15 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential new market opportunities and assess the competitive landscape for growth hormone therapies. The strongest clinical anchor is The Association Between the Stress Hormone Cortisol and Decision-making (ClinicalTrials.gov), moderate corpus alignment. In Endocrinology · Growth Hormone Deficiency, 2 regulatory and 1 competitive items passed relevance filtering for MACRILEN.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance indicates potential expansion of MACRILEN's indications, which could enhance Aeterna Zentaris' position in the endocrinology market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — MACRILEN (SUPPL) (FDA). Entity match (macrilen); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplemental NDA indicates a significant step towards potential approval, which could affect compliance and labeling for MACRILEN.

Key Risks

Elevated medium regulatory exposure for MACRILEN could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (The Association Between the Stress Hormone Cortisol and Decision-making) could weigh on MACRILEN through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If approved, the expanded indications for MACRILEN could lead to increased revenue and market share for Aeterna Zentaris, enhancing its standing in the endocrinology market.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for MACRILEN may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should prepare for potential new market opportunities and assess the competitive landscape for growth hormone therapies.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the NDA review and any announcements regarding new indications or data from Aeterna Zentaris.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — MACRILEN (SUPPL)
FDAhigh relevance
Entity match (macrilen); Regulatory pathway relevance (nda)
FDA document
View source
Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

The Association Between the Stress Hormone Cortisol and Decision-making
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Genetic Basis of Immunodeficiency
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of a brief primary care intervention for post-traumatic stress disorder symptoms after critical illness on health-related quality of life - A secondary analysis of the PICTURE randomised contr
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The association between age and mortality in men with adult-onset testosterone deficiency is altered by testosterone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

MACRILEN

Commercial impact

medium

If approved, the expanded indications for MACRILEN could lead to increased revenue and market share for Aeterna Zentaris, enhancing its standing in the endocrinology market.

Regulatory impact

medium

The acceptance of the supplemental NDA indicates a significant step towards potential approval, which could affect compliance and labeling for MACRILEN.

What to watch

Monitor the progress of the NDA review and any announcements regarding new indications or data from Aeterna Zentaris.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.